Production (Stage)
Microbix Biosystems Inc.
MBX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -11.19% | -30.13% | 45.15% | -10.18% | 33.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.19% | -30.13% | 45.15% | -10.18% | 33.96% |
| Cost of Revenue | -23.90% | 1.90% | -1.50% | -28.80% | 57.93% |
| Gross Profit | 0.19% | -41.39% | 138.07% | 15.15% | 17.93% |
| SG&A Expenses | 15.57% | -33.03% | 14.61% | -19.98% | 7.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.56% | -15.53% | 4.48% | -22.46% | 26.74% |
| Operating Income | -63.44% | -63.31% | 170.56% | 124.35% | 274.59% |
| Income Before Tax | -94.86% | -66.08% | -70.91% | 131.49% | 1,097.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.86% | -66.08% | -78.32% | 131.49% | 1,097.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.86% | -66.08% | -78.32% | 131.49% | 1,097.44% |
| EBIT | -63.44% | -63.31% | 170.56% | 124.35% | 274.59% |
| EBITDA | -33.98% | -56.32% | 217.26% | 260.34% | 103.59% |
| EPS Basic | -95.00% | -65.91% | -77.98% | 130.95% | 900.00% |
| Normalized Basic EPS | -92.31% | -66.27% | 167.57% | 111.54% | 1,200.00% |
| EPS Diluted | -95.00% | -67.42% | -77.98% | 128.89% | 900.00% |
| Normalized Diluted EPS | -92.31% | -66.27% | 167.57% | 111.54% | 1,200.00% |
| Average Basic Shares Outstanding | 1.80% | -1.10% | -0.51% | -0.51% | -0.72% |
| Average Diluted Shares Outstanding | 1.08% | -0.63% | 0.03% | 0.06% | -5.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |